Growth factors and receptors as prognostic markers in urothelial carcinoma

被引：39
作者：
Black P.C. [1 ]
Dinney C.P.N. [1 ]
机构：
[1] Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030
来源：
Current Urology Reports | 2008年 / 9卷 / 1期
关键词：
Epidermal Growth Factor Receptor; Bladder Cancer; Transitional Cell Carcinoma; Urothelial Carcinoma; Epidermal Growth Factor Receptor Expression;
D O I：
10.1007/s11934-008-0011-6
中图分类号：
学科分类号：
摘要：
Growth factors and their receptors are significant to the biology of transitional cell carcinoma of the bladder. In this context, characterization of gene expression, amplification, and mutation has established the relevance of receptors as potential targets of novel therapeutic agents. Because these characteristics vary across disease states, they may serve as prognostic indicators of recurrence, progression, response to therapy, and mortality. This review focuses on the prognostic value of the human epidermal growth factor receptor family, including epidermal growth factor receptor (EGFR), human EGFR-2 (HER2), HER3, HER4, vascular endothelial growth factor receptor (VEGFR), and fibroblast growth factor receptor-3 (FGFR3). EGFR and HER2 seem to indicate a poor prognosis, and HER4 and FGFR3 appear to be favorable prognostic indicators. However, validation studies are required to answer many remaining questions. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码：55 / 61
页数：6
相关论文
共 47 条
  • [1] Jemal A., Siegel R., Ward E., Et al., Cancer statistics, 2007, CA Cancer J Clin, 57, pp. 43-66, (2007)
  • [2] Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Et al., Primary superficial bladder cancer risk groups according to progression, mortality and recurrence, J Urol, 164, pp. 680-684, (2000)
  • [3] Habuchi T., Marberger M., Droller M.J., Et al., Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers, Urology, 66, pp. 64-74, (2005)
  • [4] Rotterud R., Fossa S.D., Nesland J.M., Protein networking in bladder cancer: Immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium, Histol Histopathol, 22, pp. 349-363, (2007)
  • [5] Memon A.A., Sorensen B.S., Meldgaard P., Et al., The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: A study in bladder cancer patients, Br J Cancer, 94, pp. 1703-1709, (2006)
  • [6] Mellon K., Wright C., Kelly P., Et al., Long-term outcome related to epidermal growth factor receptor status in bladder cancer, J Urol, 153, pp. 919-925, (1995)
  • [7] Kassouf W., Black P.C., Tuziak T., Et al., Distinctive expression patterns of ErbB family receptors signify an aggressive variant of bladder cancer, J Urol, (2007)
  • [8] Chow N.H., Liu H.S., Lee E.I., Et al., Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer, Anticancer Res, 17, pp. 1293-1296, (1997)
  • [9] Chow N.H., Liu H.S., Yang H.B., Et al., Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study, Virchows Arch, 430, pp. 461-466, (1997)
  • [10] Valentine A., Ritchie J.L., Nevin G.B., McKeown S.R., Prognostic role of P27kip1 and epidermal growth factor receptor in transitional cell carcinoma of the bladder, Uro-Oncology, 2, pp. 41-46, (2002)
12345